期刊文献+

地西他滨治疗骨髓增生异常综合征转为急性髓系白血病完全缓解1例并文献复习 被引量:1

Case report with literatures review on Decitabine treatment of myelodysplastic syndromes into acute myeloid leukemia in complete remission
下载PDF
导出
摘要 通过介绍地西他滨治疗1例骨髓增生异常综合征(myelodysplastic syndrome,MDS)转为急性髓系白血病(acutemyeloid leukemia,AML)的患者达到完全缓解的治疗过程,了解抗肿瘤新药DNA甲基化转移酶抑制剂地西他滨的疗效及副作用。地西他滨对MDS患者能明显改善生活质量,减轻输血的依赖,甚至能够使向白血病转化的MDS患者达到完全缓解,但有骨髓抑制的副作用。并通过文献复习来全面介绍近几年地西他滨的临床研究情况,为临床应用该药提供帮助。 Introduction Decitabine to treatment of patients with MDS into AML patients achieved complete remission dur- ing the treatment, in order to learn about the efficacy and side effects of anti-tumor drugs DNA methylation inhibitor Decitabine. Decitabine for MDS patients can significantly improve the quality of life, reduce transfusion dependence, even able to make the transformation to leukemia patients achieved complete remission with the side effect of bone marrow sup- pression. And a comprehensive review of the literatures is made to Decitabine clinical application in recent years, to pro- vide help for the clinical application of the medicine.
出处 《中国医药导报》 CAS 2012年第36期117-119,共3页 China Medical Herald
基金 国家自然科学基金(项目批准号:30572108) 国家自然科学基金(项目批准号:30670898)
关键词 地西他滨 骨髓增生异常综合征 急性髓系白血病 化疗 副作用 Decitabine Myelodysplastic syndrome Acute myeloid leukemia Chemotherapy Side-effects
  • 相关文献

参考文献24

  • 1Lubbert M,Suciu S,Baila L. Low-dose decitabine versus best supportive care in elderly patients with intermediate or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy:final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group[J].Clinical Oncology,2011,(15):1987-1996.
  • 2张之南;沈悌.血液学诊断及疗效标准[S]北京:科学出版社,2006279-281.
  • 3Saba HI. Decitabine in the treatment of myelodysplastic syndromes[J].Ther Clin Risk Manag,2007,(05):807-817.
  • 4Qin T,Castoro R,El AS. Mechanisms of resistance to decitabine in the myelodysplastic syndrome[J].PLos One,2011,(08):23372.
  • 5Bryan J,Kantarjian H,Garcia-Manero G. Pharmacokinetic evaluation of decitabine for the treatment of leukemia[J].Expert Opin Drug Metab Toxicol,2011,(05):661-672.
  • 6赖沛龙,杜欣,翁建宇,耿素霞,王玉春,陆泽生,钟立业,邓程新,林绍泽.骨髓增生异常综合征患者地西他滨治疗后DNA甲基化水平变化[J].临床荟萃,2012,27(2):114-117. 被引量:9
  • 7Steensma DP,Baer MR,Slack JL. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes:the alternative dosing for outpatient treatment (ADOPT) trial[J].Clinical Oncology,2009,(23):3842-3848.
  • 8De L,Lima M,Kantarjian H. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome[J].Bone Marrow Transplantation,2009,(11):839-843.doi:10.1038/bmt.2008.400.
  • 9高雅,平宝红,周淑芸.地西他滨治疗老年骨髓增生异常综合征1例并文献复习[J].南方医科大学学报,2012,32(2):280-282. 被引量:14
  • 10王磊,徐政永,吴冰,陆泳萍,方奕奇.地西他滨治疗老年骨髓增生异常综合征一例[J].临床合理用药杂志,2011,4(10X):166-166. 被引量:1

二级参考文献84

  • 1王红艳,王蓓,张丽.化疗所致口腔炎的护理及其进展[J].国外医学(护理学分册),2005,24(7):323-325. 被引量:43
  • 2肖爱军,陈素萍,时敏秀.全程心理管理程序在恶性肿瘤患者心理护理中的应用[J].护理学报,2007,14(6):83-85. 被引量:46
  • 3肖志坚.循证医学指导下的血液病规范化诊治[J].中国实用内科杂志,2007,27(14):1091-1094. 被引量:18
  • 4Robertson K D,Wolffe A.DNA methylation in health and disease[J].Nat Rev Genet,2000,1:11-19.
  • 5Jones P A,Baylin SB.The epigenomics of cancer[J].Cell,2007,128:683-982.
  • 6Jones P A,Taylor SM.Cellular differentiation,cytidine anaogs and DNA methylation[J].Cell,1980,20:85-93.
  • 7Lakshmikuttyamma A,S A Scott,DeCoteau J F,et al.Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition[J].Oncogene,2010,29:576-588.
  • 8Issa J P,Garcia-Manero G,Giles F J,et al.Phase 1 study of lowdoseprolonged xposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (dexycytidine) in hematopoietic malignancies[J].Blood,2004,103:1635-1640.
  • 9Soriano A,Champlin R,McCormick G,et al.Maintenance therapy with 5-asacitidine after allogeneic stem cell transplantation for acute myelogenous leukemia and high risk myelodysplastic syndrome:a dose and schedule finding study[J].Blood,2006,108:1048a.
  • 10Kantsrjian H,Oki Y,Garcia-Manero G,et al.Results of a randomized study of 3 schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia[J].Blood,2007,109:52-57.

共引文献74

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部